PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2010; 5(6): e11256.
Published online 2010 June 25. doi:  10.1371/journal.pone.0011256
PMCID: PMC2892485

Broad-Spectrum Matrix Metalloproteinase Inhibition Curbs Inflammation and Liver Injury but Aggravates Experimental Liver Fibrosis in Mice

Fernando Rodrigues-Lima, Editor

Abstract

Background

Liver fibrosis is characterized by excessive synthesis of extracellular matrix proteins, which prevails over their enzymatic degradation, primarily by matrix metalloproteinases (MMPs). The effect of pharmacological MMP inhibition on fibrogenesis, however, is largely unexplored. Inflammation is considered a prerequisite and important co-contributor to fibrosis and is, in part, mediated by tumor necrosis factor (TNF)-α-converting enzyme (TACE). We hypothesized that treatment with a broad-spectrum MMP and TACE-inhibitor (Marimastat) would ameliorate injury and inflammation, leading to decreased fibrogenesis during repeated hepatotoxin-induced liver injury.

Methodology/Principal Findings

Liver fibrosis was induced in mice by repeated carbon tetrachloride (CCl4) administration, during which the mice received either Marimastat or vehicle twice daily. A single dose of CCl4 was administered to investigate acute liver injury in mice pretreated with Marimastat, mice deficient in Mmp9, or mice deficient in both TNF-α receptors. Liver injury was quantified by alanine aminotransferase (ALT) levels and confirmed by histology. Hepatic collagen was determined as hydroxyproline, and expression of fibrogenesis and fibrolysis-related transcripts was determined by quantitative reverse-transcription polymerase chain reaction. Marimastat-treated animals demonstrated significantly attenuated liver injury and inflammation but a 25% increase in collagen deposition. Transcripts related to fibrogenesis were significantly less upregulated compared to vehicle-treated animals, while MMP expression and activity analysis revealed efficient pharmacologic MMP-inhibition and decreased fibrolysis following Marimastat treatment. Marimastat pre-treatment significantly attenuated liver injury following acute CCl4-administration, whereas Mmp9 deficient animals demonstrated no protection. Mice deficient in both TNF-α receptors exhibited an 80% reduction of serum ALT, confirming the hepatoprotective effects of Marimastat via the TNF-signaling pathway.

Conclusions/Significance

Inhibition of MMP and TACE activity with Marimastat during chronic CCl4 administration counterbalanced any beneficial anti-inflammatory effect, resulting in a positive balance of collagen deposition. Since effective inhibition of MMPs accelerates fibrosis progression, MMP inhibitors should be used with caution in patients with chronic liver diseases.

Introduction

Hepatic fibrosis represents the wound healing response to chronic insult and is the final common pathway for most chronic liver diseases, regardless of their mechanism [1][3]. Progressive fibrosis ultimately leads to increased mortality and morbidity from portal hypertension, end-stage liver failure and ultimately cirrhosis, and is associated with an increased risk of hepatic malignancies [4]. Currently, the only definitive treatment for advanced fibrosis and cirrhosis is liver transplantation; however, the demand for organ grafts outweighs their availability [5], stressing the need for effective antifibrotic approaches [6], [7].

Hepatocellular injury usually leads to inflammation and activation of the innate immune system, leading to release of growth factors, cytokines and small molecular mediators that can stimulate extracellular matrix (ECM) synthesis by activation of quiescent hepatic stellate cells and fibroblasts/myofibroblasts (collectively named HSCs) [1], [2]. Upon fibrogenic activation, HSCs as well as inflammatory cells release and respond to the cytokine transforming growth factor (TGF)-β [8]. TGF-β strongly upregulates production and deposition of the major ECM constituents, while it downregulates fibrolytic matrix metalloproteinases (MMPs) [8], [9]. In the presence of chronic hepatic injury, an imbalance between fibrogenesis and fibrolysis may lead to excess ECM deposition and scar formation.

Cell surface-bound and soluble MMPs along with their endogenous tissue inhibitors (TIMPs) constitute an important system for regulating ECM turnover; however, MMPs also regulate inflammatory processes [10]. Chronic inflammation is an important driver in fibrogenesis, serving both as a trigger and perpetuator of fibrosis progression [11]. A critical mediator of the inflammatory response is tumor necrosis factor (TNF)-α, which exists in a biologically active, soluble form and as an inactive, membrane-anchored precursor [12]. Cleavage of the TNF-α proform into its soluble form is mediated by TNF-α-converting enzyme (TACE, also known as ADAM17 and CD156b), which belongs to the disintegrin and metalloproteinase (ADAM) family of zinc-metalloproteinases [13], [14]. Mice deficient in TIMP3, the endogenous physiological inhibitor of TACE [15], demonstrate elevated levels of TNF-α and develop severe inflammation of the liver, presumably due to depressed TACE activity [16]. In contrast, pharmacologic TACE-inhibition abrogates the inflammatory response and has been demonstrated to have therapeutic potential in a variety of pathological conditions [17], [18]. Many TACE-inhibitors, however, are relatively non-specific and also inhibit various MMPs.

MMPs are widely believed to be important players in fibrosis due to their collagen-cleaving activity [19][21]. Identification of novel MMP substrates, however, revealed their involvement in highly complex processes such as the regulation of cell behavior, cell-cell communication, and tumor progression [22], [23]. Hence, these insights indicate that MMPs have a much more complex function in fibrosis than merely ECM degradation. Effects of MMP-inhibition on fibrogenesis, however, remain to be established. We hypothesized that treatment with a broad-spectrum MMP and TACE-inhibitor would ameliorate both injury and inflammation, resulting in decreased fibrosis formation in a murine model of repeated carbon tetrachloride (CCl4) administration.

Results

Chronic broad-spectrum MMP-inhibition dramatically reduces histological liver injury in mice subjected to chronic CCL4-intoxication

Chronic CCl4-administration resulted in liver enlargement and fibrosis (Figure 1A). Liver sections of vehicle treated controls exhibited areas of necrosis, steatosis, and inflammatory lymphocytic infiltrates –hallmarks of severe chronic hepatic injury (Figure 1B). Liver sections from Marimastat treated animals, however, showed a significant reduction in steatosis (Figure 1C), inflammation (Figure 1D) and necrosis (Figure 1E), suggesting attenuation of hepatic injury and inflammation, despite a loss of body weight (Figure 1F).

Figure 1
Marimastat treatment reduced liver injury, necrosis, and inflammation following repeated carbon tetrachloride (CCl4) administration.

Marimastat treatment markedly blunts the increase of serum ALT and levels of TNF-α receptor II in CCl4-induced chronic hepatic injury

Marimastat treatment resulted in a 1.4-fold reduction of alkaline phosphatase levels (P≤0.05, Figure 2A) and a 14-fold decrease in serum ALT levels (P≤0.05, Figure 2B), indicating markedly decreased hepatic injury following repeated CCl4-administration. Serum levels of soluble TNF-α receptor II (p75) were 1.2-fold decreased in Marimastat treated animals (P≤0.05), likely reflecting pharmacologic inhibition of TACE and an ameliorated inflammatory response (Figure 2C) [22], [24]. Serum IL-6 levels were increased 2.9-fold (P≤0.05), suggesting hepatoprotection and stimulated liver regeneration (Figure 2D) [25].

Figure 2
Marimastat treatment ameliorated hepatic injury and the inflammatory response following repeated carbon tetrachloride (CCl4) administration.

Marimastat treatment leads to downregulation of major pro-fibrogenic genes

Hepatic expression of procollagen α1(I), β6 Integrin, TGF-β1, TGF-β2, alpha-smooth muscle actin (α-SMA) and TIMP-1 mRNA were strongly upregulated following repeated CCl4-administration (Figure 3). Concomitant treatment with Marimastat, however, significantly decreased hepatic transcript levels of procollagen α1(I) (Figure 3A), TGF-β2 (Figure 3D), α-SMA (Figure 3E) and TIMP-1 (Figure 3F) compared to vehicle treated controls, whereas β6 Integrin (Figure 3B) and TGF-β1 (Figure 3C) mRNA levels remained unchanged.

Figure 3
Marimastat altered the hepatic fibrosis-related gene expression profile by downregulation of multiple pro-fibrogenic transcripts following repeated carbon tetrachloride (CCl4) administration.

Marimastat does not diminish net collagen deposition and fibrosis formation

Treatment of mice with Marimastat during chronic CCl4-administration significantly increased the liver and the spleen (a putative marker of portal hypertension) to body weight ratios, compared to controls (Figure 4A, B). Liver sections of the vehicle treated controls exhibited centrilobular fibrosis with areas of necrosis, whereas liver sections from Marimastat treated animals showed enhanced centrilobular collagen deposition indicating increased fibrosis formation (Figure 4C). To directly quantify the degree of fibrosis, we measured both relative (per g of liver) and total (per whole liver) collagen content biochemically via hepatic hydroxyproline determination. Marimastat treatment resulted in a significant increase in relative and total collagen (hydroxyproline) content (25% and 14%, respectively) compared to the controls (Figures 4D, E). This was corroborated using morphometric analysis of Sirius Red stained liver sections (Figure 4F), demonstrating that the relative fibrotic area was significantly increased in livers from mice treated with Marimastat, compared to controls (4.2% versus 3.1%, respectively; P<0.05). These results suggest dissociation between hepatic injury and inflammation on the one hand, and the degree of fibrosis on the other hand, upon pharmacological MMP inhibition.

Figure 4
Marimastat treatment increased hepatic fibrosis following repeated carbon tetrachloride (CCl4) administration.

Marimastat decreases hepatic stellate cell activation, but increases recruitment of inflammatory cells

Immunohistochemical staining for α-SMA (Figure 5A), as a marker for activated HSCs, was performed to confirm the observed decrease in α-SMA mRNA (Figure 3E). α-SMA positive cells were significantly increased following chronic CCl4-administration; however, concomitant treatment with Marimastat significantly decreased this number indicating decreased activation of a subset of activated HSCs (Figure 5A,B). This again suggests that Marimastat treatment led to a decrease in fibrogenic activity, which is in dissociation with the observed, net result of increased fibrosis (Figure 4). To further explore this finding, immunohistochemical staining for T-cells and macrophages (i.e., Kupffer cells) was performed. Chronic administration of CCl4 induces an inflammatory response, elicited by accumulation of T-cells and macrophages that remove injured hepatocytes and stimulate fibroblast function [26]. Immunohistochemical staining for CD3 (Figure 5C), as a marker for T-cells, revealed a 1.8-fold increase in cell counts in Marimastat-treated animals that were subjected to chronic CCl4-administration (Figure 5D). In addition, cell counts from F4/80 positive cells, as a marker for macrophages, revealed a 1.8-fold increase following treatment of mice with Marimastat during chronic CCl4-administration (Figure 5E,F).

Figure 5
Marimastat decreases hepatic stellate cell (HSC) activation, but increases recruitment of inflammatory cells.

Marimastat treatment downregulates MMP gene expression and MMP-activities

To better understand the increased ECM deposition in animals treated with Marimastat, we analyzed hepatic MMP expression levels. In fibrotic animals, hepatic expression of MMP-2, MMP-3, MMP-8, MMP-9 and MMP-13 mRNA were all significantly upregulated, compared to non-fibrotic controls (Figure 6). Marimastat treatment during chronic CCl4 administration, however, did not affect hepatic transcript levels of MMP-2 (Figure 6A), or MMP-3 (Figure 6B), compared to vehicle treated animals. Hepatic transcript levels of MMP-8 (Figure 6C) and MMP-9 (Figure 6D) were 5.6-fold and 6.6-fold increased, respectively, in livers from Marimastat treated animals, whereas hepatic MMP-13 transcripts were 3.0-fold higher in the vehicle treated animals (Figure 6E). Increased MMP expression levels may have resulted from a positive feedback mechanism resulting from efficient pharmacologic inhibition of MMP-activity, although this would not explain downregulation of MMP-13 [22]. We therefore performed an assay to investigate the ability of Marimastat to inhibit gelatinase (MMP-2, MMP-9) and interstitial collagenase (MMP-1) activities. Relative collagenase activity as well as relative interstitial gelatinase activity in liver homogenates supplemented with increasing concentrations of Marimastat showed a dose-dependent inhibition of both these MMP-activities (Figure 6F). These findings indicate efficient inhibition of putatively fibrolytic MMPs by Marimastat, potentially leading to increased fibrosis in the presence of continuous hepatic injury.

Figure 6
Marimastat treatment downregulates matrix metalloproteinase (MMP) gene expression and MMP-activities.

Broad spectrum MMP-inhibition with Marimastat using a model of acute administration of a single dose of CCl4 predicts the evolution of the chronic CCl4 model

To further explore the anti-inflammatory and hepatoprotective potential of pharmacologic broad-spectrum MMP and TACE inhibition, C57Bl/6J mice were pretreated for 7 days with Marimastat and subsequently challenged with a single dose of CCl4. Analysis of liver sections at 12 h, 24 h, 48 h and 96 h time points revealed that acute CCl4 intoxication resulted in severe necroinflammatory injury around the central vein areas with a peak at 24 h, regeneration and repair at 48 h characterized by influx of macrophages and inflammatory lymphocytic infiltrates, and impressive resolution of necrotic injury after 96 h (data not shown). After 24 h, Marimastat pre-treatment attenuated necroinflammatory hepatic injury as determined by histology (Figure 7A), and resulted in a 57% reduction in serum ALT levels (P≤0.05, Figure 7B). Since the peak of hepatic injury occurred after 24 h, this time point was chosen as surrogate endpoint in subsequent experiments.

Figure 7
Marimastat reduces necroinflammatory injury following a single dose of carbon tetrachloride (CCl4) via a TNF-dependent pathway.

Marimastat reduces necroinflammatory injury following a single dose of CCl4 via a TNF-dependent pathway

Next, we studied if the anti-inflammatory and hepatoprotective effects of Marimastat could be attributed to either an MMP- or a TACE- dependent mechanism by using gene deleted animals. MMP-9 is the major and most studied and abundant MMP in inflammation [10], [27], playing a critical role in fulminant TNF-mediated hepatitis [28], mediating hepatic ischemia/reperfusion injury [29] and being involved in liver regeneration [30]. Given that Marimastat efficiently inhibits MMP-9 activity (Figure 6), Mmp9 homozygous null mice (Mmp9−/−) and their WT littermates were subjected to a single dose of CCl4, or vehicle (mineral oil) to investigate the involvement of a single MMP, rather than multiple MMPs by pharmacologic broad-spectrum MMP-inhibition on CCl4-induced hepatotoxicity. After 24 h liver sections from WT animals and Mmp9−/− animals exhibited extensive centrilobular necroinflammatory changes (Figure 7C). Serum ALT levels were 28,410 IU/L in WT animals compared to 28,100 IU/L in Mmp9−/− animals (P = 0.89; Figure 7D). Taken together, these findings do not indicate that MMP-9 plays a significant role in the acute phase of CCl4-induced hepatic injury.

The ability of Marimastat to inhibit TACE activity prompted us to study the role of TNF-α signaling in CCl4-induced acute hepatotoxicity. Since TACE is one of the major activators of TNF-α, TACE-inhibition has been implicated as a promising anti-inflammatory approach [17], [24]. Because homozygous TACE deletion is embryologically lethal [31], mice deficient in both TNF-α receptors (TNF p55−/− p75−/−) and their WT littermates were used and subjected to either a single dose of CCl4 or mineral oil, and sacrificed after 24 h to evaluate hepatic injury. Liver sections from TNF p55−/− p75−/− mice revealed a marked reduction of necroinflammatory injury, compared to WT controls (Figure 7E). These findings were corroborated by a marked, 80% reduction of serum ALT levels in TNF p55−/− p75−/− mice, compared to CCl4-injected WT controls (4,581 IU/L and 22,660 IU/L, respectively, P≤0.05; Figure 7F). This implicates the involvement of TNF-signaling in CCl4-induced hepatic injury and provides a mechanistic explanation for the hepatoprotective effects of Marimastat in both acute, and chronic CCl4-induced hepatic injury.

Discussion

The present study was aimed to determine the effects of the broad spectrum MMP-inhibitor Marimastat on fibrosis formation in a murine model of repeated, chronic CCl4-induced hepatic injury. We demonstrate that pharmacologic pan-MMP inhibition very efficiently decreased hepatic injury by amelioration of the inflammatory response and by downregulation of pro-fibrogenic mRNA expression, through interfering, at least in part, with TNF-α activation and signaling. The detrimental effects of MMP-inhibition on scar formation, however, were unexpected. We initially hypothesized that inhibition of MMP activity would lead to a further decrease in hepatic injury, rather than impacting on collagen accumulation, resulting in decreased fibrosis formation. Obviously, broad spectrum MMP-inhibition, as determined by MMP transcript levels and activity assays, counterbalanced the potential beneficial anti-fibrogenic and anti-inflammatory effects by efficient inhibition of fibrolysis (Figure 8). This dissociation between inflammation and liver injury on the one hand, and fibrolysis on the other hand has to our knowledge not been described previously and may provide novel insights in the dual role of MMPs in fibrogenesis, and fibrolysis.

Figure 8
Broad-spectrum matrix metalloproteinase (MMP)-inhibition results in increased hepatic fibrosis following chronic hepatic injury.

MMPs are secreted as zymogens and become activated by cleavage of their propeptide [32], [33]. Marimastat is a synthetic, low molecular weight succinyl hydroxamate that inhibits MMPs via its hydroxamate group that complexes the zinc ion needed in the active site of MMPs [27]. Marimastat also inhibits TACE, with a suggested benefit in diseases that involve both inflammation and extracellular matrix remodeling [34]. Although MMPs were traditionally viewed as molecules that were only involved in degradation and turnover of the extracellular matrix, novel insights overturned this dogma and revealed that MMPs modulate the activities of a wide range of extracellular and intracellular signaling pathways [22], [23]. By regulating cell proliferation, migration, adhesion, growth factor bioavailability, chemotaxis, and cell signaling, MMPs are crucial for physiological and pathophysiological processes such as inflammation, immunity, angiogenesis, tumorigenesis, metastasis, and wound healing. As a consequence, a broad spectrum MMP inhibitor such as Marimastat was expected to have both anti-inflammatory and potential antifibrotic properties.

It has been generally accepted that changes in patterns of matrix degradation are critical for fibrogenesis [35]; however, the role of MMP activity in the liver during fibrogenesis is not yet fully understood. In rodents, MMP-2, MMP-3, MMP-9, MMP-13, MMP-14, as well as TIMP-1 and TIMP-2 are expressed in early stages of HSC activation and have been implicated in fibrogenesis as well as fibrolysis (reviewed in [20]). We confirmed that the broad-spectrum MMP-inhibitor Marimastat efficiently inhibited gelatinolytic and collagenolytic MMP, as well as TACE activities. Among other pro-fibrogenic genes, hepatic transcript levels of α-SMA were significantly decreased in the Marimastat treated animals suggesting decreased activation of a subset of HSCs and ameliorated fibrogenesis. This was confirmed by immunohistochemical staining for α-SMA followed by quantification of positive cell counts. It must be noted, however, that there exists heterogeneity of gene expression in myofibroblastic cells during fibrogenesis which reduces the usefulness of α-SMA as a marker for collagen production [36]. MMPs such as MMP-8, MMP-9, and MMP-13 possess the ability to degrade the extracellular matrix by breakdown of fibrillar collagen type I [9], [19], [37]. MMP-9 may indirectly contribute to fibrolysis by accelerating HSC apoptosis, whereas MMP-2 may rather drive hepatic stellate activation and unfavorable basement membrane remodeling resulting in more fibrosis [20], [38]. We demonstrated efficient inhibition of gelatinolytic and collagenolytic MMP-activities which as a whole has shifted the balance towards a net accumulation of hepatic fibrosis.

TIMP-1 is the most relevant physiological MMP-inhibitor in fibrotic diseases, including hepatotoxic and cholestatic injury, whose expression is upregulated by various inflammatory cytokines [32], [33]. Antagonizing TIMP-1 using both neutralizing antibodies and gene therapy, as well as indirect TIMP-1 mRNA reduction by antagonizing inflammatory cytokines improved experimental fibrosis in rodents [20]. In addition, transgenic mice overexpressing human TIMP-1 developed more liver fibrosis when subjected to chronic CCl4 administration [39], and demonstrated attenuated spontaneous fibrosis resolution [40]. Reduced TIMP-1 levels may also accelerate hepatocyte proliferation following partial hepatectomy, illustrating its inhibitory role in hepatocyte regeneration [41]. In our study, inflammation was significantly decreased by TACE inhibition while downregulation of TIMP-1 may have further improved hepatic regeneration, as reflected by the marked decrease in serum levels of alkaline phosphatase and ALT.

To further elucidate the hepatoprotective effects of broad spectrum MMP-inhibition, we dosed Marimastat-pretreated C57Bl/6J mice with a single injection of CCl4, to demonstrate reduced centrilobular necrosis and a marked (57%) reduction in serum ALT levels corroborating the hepatoprotective effects of Marimastat also in acute liver failure. These data are in line with a previous report describing the use of a similar broad-spectrum MMP-inhibitor (Batimastat; BB-94, British Biotech) in the prevention of acute, fulminant hepatitis induced by TNF-α combined with d-(+)-galactosamine [28]. In this study, mice treated with BB-94 as well as mice deficient in Mmp2, Mmp3 or Mmp9 had lower levels of apoptosis and necrosis of hepatocytes, and better survival. Although TACE inhibitors are efficient in protecting against lipopolysaccharide/d-(+)-galactosamine-induced lethal hepatitis by inhibition of TNF-α release, inhibition of TACE by BB-94 was deemed irrelevant in their model; however, data was not shown [28]. The authors speculated that the absence or presence of endogenous TNF-α does not influence the outcome after TNF-α/d-(+)-galactosamine challenge [28].

Observations that soluble TNF-α receptor treatment improved the outcome following acute CCl4-intoxication [42], and that monoclonal antibodies against TNF-α improved experimental CCl4-induced fibrosis [43] led us to explore the involvement of TNF-α and TACE in CCl4-mediated hepatotoxicity. We show that after a single dose of CCl4, animals pretreated with the broad-spectrum MMP- and TACE-inhibitor Marimastat, as well as animals deficient in both TNF-α receptors (p55 and p75) were markedly protected, as demonstrated by attenuated necroinflammatory injury on histology and 5-fold lower serum ALT levels, compared to their wild type controls. These findings indicate the pivotal role of TNF-α signaling in CCl4 mediated hepatotoxicity. A previous study failed to demonstrate a significantly ameliorated response of TNF p55−/− p75−/− mice to acute CCl4 intoxication [44], which is in contrast with our results. But these authors and others found reduced fibrogenesis following repeated CCl4-administration in animals lacking the TNF-α p55 receptor supporting the involvement of TNF-signaling in CCl4-mediated hepatotoxicity [44], [45]. These data suggest that specific inhibition of TACE may be an attractive approach to manipulate the inflammatory cascade following a hepatic insult.

We also explored the possible involvement of MMP-9 in the protection against acute CCl4-induced injury. A previous report showed that acute CCl4-induced liver injury in rats increased both active and latent MMP-9 to maximum levels at 24 h and remained elevated 3 days following the injection, suggesting its involvement in early hepatic injury [46]. We show that after a single dose of CCl4 animals deficient in Mmp9 exhibited similar hepatic injury compared to their wild type controls, as assessed by histology and serum ALT levels after 24 h. The interpretation of results with MMP knockout mice, however, is difficult since the net proteolytic activity of MMPs relies upon complex, direct interactions between the different protease and protease inhibitor families. In addition, adaptive upregulation of gelatinolytic/collagenolytic activities can have occurred, which would necessitate a conditional knockout. Nevertheless, the almost identical results of both Mmp9−/− animals and their wild type controls largely rules out a major role of MMP-9 in the protection against acute CCl4 intoxication.

More recently, another paper described attenuation of liver injury following treatment with the MMP-inhibitor CTS-1027 (Conatus Pharmaceuticals, San Diego, CA, USA)[47]. Using the bile duct ligation model, a decrease in hepatocyte apoptosis and a reduction in markers for HSC activation and fibrogenesis was demonstrated, which is in line with our results that Marimastat attenuated hepatic inflammation and necrosis coupled with downregulation of genes related to fibrogenesis. CTS-1027 is actually now being further evaluated as a potential drug in patients with Hepatitis C Virus [48]; however, we believe that in light of our results caution is warranted. Although it was demonstrated that two weeks of treatment with CTS-1027 resulted in attenuation of collagen deposition in the bile duct ligation model, we found that inhibition of MMP- and TACE-activity with Marimastat during chronic CCl4 administration for 6 weeks resulted in increased net fibrosis. It is well possible that two weeks of MMP-inhibition may attenuate injury without aggravating fibrosis, while longer-term treatment in the presence of ongoing liver injury may shut down matrix degradation, eventually leading to impaired fibrolysis. Although we cannot extrapolate our results with Marimastat to all MMP inhibitors and potential off-target effects of Marimastat may have contributed to our findings, it is likely that long-term use of all such inhibitors with anti-TACE activity will have similar divergent effects on liver injury and fibrosis.

Clinically, Marimastat has been used in multiple oncologic clinical trials up to phase III; however, its overall therapeutic benefit was limited and the trials were halted [49][51]. The most consistently reported side effect was musculoskeletal pain, likely due to inhibition of adaptive ECM remodeling; however, spontaneous fibrosis formation has never been reported. This suggests that in the absence of chronic hepatic injury such as hepatitis, or non-alcoholic steatohepatitis, broad-spectrum MMP-inhibition is unlikely to be harmful to the liver. This may also apply to other MMP-inhibitors such as the commonly prescribed antibiotic doxycycline [52], [53]. Nonetheless, we believe that caution is warranted when patients with chronic, active liver diseases receive MMP-inhibitors, since inhibition of fibrolytic MMPs will likely accelerate hepatic fibrogenesis formation.

In conclusion, we demonstrate that broad-spectrum MMP- and TACE-activity inhibition with Marimastat during chronic CCl4 administration resulted in significantly attenuated hepatic inflammation and necrosis coupled with downregulation of genes related to fibrogenesis, but resulted in increased liver fibrosis. Inhibition of MMPs and collagen degradation by Marimastat, however, counterbalanced the beneficial anti-inflammatory effect, resulting in a positive balance of collagen deposition. Since effective inhibition of fibrolytic activity by MMPs accelerates fibrosis progression, our data suggests a note of caution for the use of broad-spectrum MMP inhibitors in patients with chronic, ongoing liver diseases, or for the treatment of liver fibrosis itself. Specific inhibition of TACE, however, may still be an attractive approach to manipulate the inflammatory cascade following a hepatic insult.

Methods

Ethics statement

Animal protocols complied with the National Institutes of Health Animal Research Advisory Committee guidelines and were approved by the Children's Hospital Boston Animal Care and Use Committee (protocol no. A06-08-065R).

Animals

Male 6-week-old C57BL6/J mice (Jackson Laboratories, Bar Harbor, ME) were housed five per cage on paper chip bedding in a barrier room with regulated temperature (21°C±1.6°C), humidity (45%±10%), and an alternating 12-hour light and dark cycle. The animals had free access to water and standard American Institute of Nutrition (AIN) 93 M (TD.94048; Harlan Teklad, Madison, WI) purified rodent diet throughout the study.

Animal experiments

After one week of acclimation, 40 C57BL6/J mice were randomized into 4 groups (10 mice each). The first week, two groups received 100 mg/kg of Marimastat (BB-2516, British Biotech, UK) in 0.45% methylcellulose (Sigma-Aldrich, St. Louis, MO) vehicle twice daily via orogastric gavage (MAR), and two groups received vehicle alone (VEH). These treatments were continued until study completion. Marimastat efficiently inhibits MMP-2, MMP-3, MMP-7, MMP-9, MMP-13 and TACE activity, with IC50s in the nM range [26], [54]. After one week of treatment with either Marimastat or vehicle, animals received three intragastric doses via oral gavage (Monday, Wednesday and Friday) of CCl4 (anhydrous, ≥99.5%, Sigma-Aldrich, St. Louis, MO) dissolved in mineral oil (Sigma-Aldrich, St. Louis, MO) or vehicle alone each week for another six weeks. The initial dose was 0.875 mL/kg, followed by 8 doses of 1.75 mL/kg and 9 doses of 2.5 mL/kg, respectively. At the end of the seven week treatment period and three days after the last dose of CCl4, animals were sacrificed to evaluate hepatic fibrosis and related parameters (Figure 9A).

Figure 9
Design of the studies.

In separate experiments, the effect of MMP inhibition on acute liver injury was studied in 64 C57BL6/J mice after orogastric administration of a single dose of 1.5 mL/kg CCl4. Starting one week prior to the hepatotoxic challenge, 32 mice received 100 mg/kg of Marimastat twice daily via orogastric gavage (MAR), and 32 mice received vehicle alone (VEH). Treatment was continued until sacrifice. Animals were sacrificed 12 h, 24 h, 48 h and 96 h after CCl4 administration (n = 8 per treatment and time point) to evaluate hepatic injury (Figure 9B). Since the peak of hepatic injury occurred after 24 h, this time point was chosen as surrogate endpoint in subsequent experiments.

The contribution of MMP and TACE-dependent pathways was studied using mice deficient in MMP-9, as well as mice deficient in both TNF-α receptors. Thirty mice homozygous null for the Mmp9 gene (B6.FVB(Cg)-Mmp9tm1Tvu/J mice; Jackson Laboratories, Bar Harbor, ME) and their wild type (WT) littermates, and 30 mice homozygous for both TNF-α receptor I (Tnfrsf1atm1Imx; p55) and TNF-α receptor II (Tnfrsf1btm1Imx; p75) null mutations (B6;129S-Tnfrsf1atm1Imx Tnfrsf1btm1Imx/J; Jackson Laboratories, Bar Harbor, ME) and their WT littermates were subjected to either a single dose of 1.5 mL/kg CCl4 via orogastric gavage, or mineral oil (Figures 9C, D). Animals were sacrificed after 24 h to evaluate hepatic injury.

Sample collection and serum biochemistry

Animals in all groups were euthanized, and pieces of their livers fixed in 10% formalin for histology or immediately frozen and stored for RNA extraction and hydroxyproline measurements. Blood was collected via retro-orbital sinus puncture and plasma was obtained via centrifugation. Serum was frozen at -80°C for analysis of alanine aminotransferase (ALT) and alkaline phosphatase (AP) activities at the Clinical Laboratory of Children's Hospital Boston. Serum levels of IL-6 and the soluble TNF-α receptor II (p75) were determined using a commercial ELISA kit (Quantikine, R&D Systems, Minneapolis, MN). Optical density was read at 450 nm and analyzed with Softmax PRO Software (Molecular Devices, Sunnyvale, CA).

Histology

Paraffin-embedded sections from the frontal lobes of the liver were stained by hematoxylin and eosin (H&E) to examine cellular architecture and lipid accumulation. A pathologist (VN) blinded to the treatment groups conducted a histological analysis of the liver sections [55]. Lobular inflammation was quantified by assessing the number of inflammatory foci per microscopic field. Five fields were checked at 200× magnification as follows: 0 (absent), 1 (<2 foci), 2 (2–4 foci), and 3 (>4 foci). Steatosis was scored by the percentage (%) of liver cells containing fat: 0 (<5%), 1 (5–33%), 2 (>33–66%) and 3 (>66%). Necrosis was scored as 0 (absent) or 1 (pericentral area occupied by necrosis).Masson trichrome (MT) and Sirius Red stains of paraffin-embedded sections were used to qualitatively assess collagen architecture and extent of fibrosis. Morphometric analysis for fibrosis quantification was performed using ten random high power fields (HPF) per animal at 200× magnification. These images were quantified using NIH ImageJ software (http://rsb.info.nih.gov/ij/).

Immunohistochemistry

Immunohistochemistry was performed using 4 µm thick formalin-fixed, paraffin-embedded tissue sections. Briefly, slides were soaked in xylene, passed through graded alcohols and put in distilled water. Slides were then pre-treated with 1.0-mM EDTA, pH 8.0 (Zymed, South San Francisco, CA) for anti-CD3 or Citrate buffer for anti-alpha smooth muscle actin (α-SMA) in a steam pressure cooker (Decloaking Chamber, BioCare Medical, Walnut Creek, CA) as per manufacturer's instructions followed by washing in distilled water. All further steps were performed at room temperature in a hydrated chamber. Slides were pre-treated with Peroxidase Block (DAKO USA, Carpinteria, CA) for 5 minutes to quench endogenous peroxidase activity. For CD3, polyclonal rabbit anti-murine CD3 antibody (Cell Marque, Rocklin, CA. Cat #CMC363) was applied 1[ratio]1500, and for α-SMA, rabbit anti-murine α-SMA (Abcam, Cambridge, MA, Cat #ab5694) was applied 1[ratio]200 in diluent (DAKO) for 1 hour. Slides were washed in 50-mM Tris-Cl, pH 7.4, and antigens detected with anti-rabbit Envision+ kit (DAKO) as per manufacturer's instructions. After further washing, immunoperoxidase staining was developed using a DAB chromogen (DAKO) and counterstained with hematoxylin. For F4/80 staining, slides were incubated with proteinase K applied 1[ratio]5 in DAKO diluent for 10 minutes and then washed in 50-mM Tris-Cl, pH 7.4, followed by incubation with rat F4/80 antibody (Serotec, Raleigh, NC, cat# MCA497GA) applied 1[ratio]10,000 in DAKO diluent for 1 hour. Slides were then washed and incubated with rabbit anti-rat secondary (DAKO) diluted 1[ratio]750 for 30 minutes, washed, and detected with anti-rabbit Envision+ kit (DAKO) as described above. For quantification purposes, positive cells were counted in ten random HPF per animal at 200× magnification and expressed as mean positive cells/10 HPF.

Liver hydroxyproline determination

Hepatic collagen content was quantified biochemically by determining liver hydroxyproline using an established method with minor modifications [56][58]. Briefly, snap-frozen liver tissue from two different lobes (50–60 mg each) was hydrolyzed at 110°C for 16 h in 5 mL 6N HCl. The hydrolysate was filtered, 50-µL aliquots were evaporated under vacuum, and the sediment was dissolved in 1.2 mL of 50% isopropanol and incubated with 0.2 mL of 0.84% chloramine-T in 42 mmol/L sodium acetate, 2.6 mmol/L citric acid, and 39.5% (vol/vol) isopropanol (pH 6.0), followed by incubation for 10 minutes at room temperature. Next, 0.248 g p-dimethylaminobenzaldehyde, dissolved in 0.27 mL of 60% perchloric acid, and 0.73 mL isopropanol were added and incubated at 50°C for 90 minutes. Relative hydroxyproline (µg/g liver) was then quantified photometrically at 558 nm and total hydroxyproline (mg/whole liver) was calculated based on individual liver weights and the corresponding relative hydroxyproline content from representative liver samples, as established previously [57], [58].

Quantitative Real-Time RT-PCR

200–300 mg snap-frozen liver tissue from two lobes was homogenized; total RNA was extracted using Tri Reagent (Molecular Research Center, Cincinnati, OH) and reverse transcribed as described [58], [59]. Relative transcript levels were quantified by real-time RT-PCR on a LightCycler 1.5 instrument (Roche, Mannheim, Germany) using the TaqMan methodology as described in detail [57][59]. TaqMan probes (dual-labeled with 5′-FAM and 3′-TAMRA) and primers were designed based on published sequences (Table 1) using the Primer Express software (Perkin Elmer, Wellesley, USA), synthesized at MWG Biotech AG (Ebersberg, Germany), and are published elsewhere [57], [59]. The housekeeping gene beta-2 microglobulin (β2MG) was amplified in parallel reactions for normalization.

Table 1
Primers and probes used in quantitative real-time RT-PCR.

Gelatinase and Interstitial Collagenase Activity Assays

Determination of gelatinase and interstitial collagenase activity was performed as described previously with assays based on degradation of DQ-gelatin and DQ-collagen type I, respectively (Molecular Probes Inc., Eugene, OR) [58], [59]. DQ-substrates are heavily labeled with FITC which quenches their fluorescence, but fluorescent peptides are generated upon proteolytic cleavage. 20 µL of 10% liver homogenates prepared as described previously[57] were diluted in a total volume of 200 µL of MMP-activity buffer (50 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl2, 0.025% Brij 35™, pH 7.5, supplemented with EDTA-free protease inhibitor cocktail (Complete™, Roche Applied Science, Mannheim, Germany)) and incubated with DQ-substrates (25 µg/mL) and increasing doses of Marimastat dissolved in H2O at room temperature for 1–20 h in 96-well plates in triplicates. Fluorescence was measured using the Wallac Victor2 Multilabel Counter (PerkinElmer, Inc., Waltham, MA); with excitation at 485 nm, and emission at 535 nm. Human recombinant activated MMP-1 (collagenase) and MMP-2 (gelatinase) were used as positive controls. Since all procedures including extraction were performed in the presence of protease inhibitors to prevent ex vivo MMP activation, data obtained represent the net endogenous gelatinolytic and collagenolytic activities.

Statistical analysis

Data are expressed as means ± standard error of the mean (SEM). Data sets involving more than two groups were assessed by analysis of variance (ANOVA). Differences between two groups were assessed using the unpaired two-tailed Student's t test, or if nonparametric, by using the Mann-Whitney U test. P≤0.05 was considered statistically significant. All data were collected in a computerized Microsoft Excel database (Microsoft Inc., Redmond, WA). The analysis was performed with SPSS version 16.0 (SPSS Inc., Chicago, IL) statistical software, and figures were created using GraphPad Prism version 5.0 (GraphPad Software Inc., La Jolla, CA) software.

Acknowledgments

The authors are grateful to graphic artist Kristin Johnson (Children's Hospital Boston, Boston, MA) for excellent assistance with photography.

Footnotes

Competing Interests: A patent has been submitted by Children's Hospital Boston for the treatment of steatosis with the drug Marimastat. This manuscript shows the dangers of this drug in the setting of inflammation and fibrosis, since it worsens the problem. The authors have no other proprietary information on the drug, therefore everything they know about it can be shared and is being shared with the reader of the manuscript. The drug is not owned by the authors or this institution. It was obtained from British Biotech (United Kingdom), and the drug and all rights were transferred to Vernalis (United Kingdom). Since Vernalis owns this drug, an interested party may contact the company and work out an agreement with them to obtain the drug. This agreement is the material transfer agreement (MTA). This is a common practice with proprietary drugs that are not on the market. Any and all information the authors have about the drug is open for disclosure from the authors but, as mentioned, is all in the manuscript.

Funding: Dr. de Meijer was recipient of fellowships from the foundations Stichting Prof. Michael-van Vloten Fonds (Venray, The Netherlands), VSBfonds (Utrecht, The Netherlands), Gerrit Jan Mulder Stichting (Rotterdam, The Netherlands), Prins Bernhard Cultuurfonds (Amsterdam, The Netherlands), and Dr Saal van Zwanenberg Stichting (Oss, The Netherlands). Dr. Puder was supported by the Children's Hospital Surgical Foundation (Boston, MA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655–1669. [PMC free article] [PubMed]
2. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–218. [PMC free article] [PubMed]
3. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838–851. [PMC free article] [PubMed]
4. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med. 2004;350:1646–1654. [PubMed]
5. Adam R, Hoti E. Liver transplantation: the current situation. Semin Liver Dis. 2009;29:3–18. [PubMed]
6. Albanis E, Friedman SL. Antifibrotic agents for liver disease. Am J Transplant. 2006;6:12–19. [PubMed]
7. Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology. 2009;50:1294–1306. [PubMed]
8. Wells RG. Fibrogenesis. V. TGF-beta signaling pathways. Am J Physiol Gastrointest Liver Physiol. 2000;279:G845–850. [PubMed]
9. Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2000;279:G245–249. [PubMed]
10. Manicone AM, McGuire JK. Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol. 2008;19:34–41. [PMC free article] [PubMed]
11. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest. 2007;117:539–548. [PMC free article] [PubMed]
12. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334:1717–1725. [PubMed]
13. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385:729–733. [PubMed]
14. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature. 1997;385:733–736. [PubMed]
15. Amour A, Slocombe PM, Webster A, Butler M, Knight CG, et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 1998;435:39–44. [PubMed]
16. Mohammed FF, Smookler DS, Taylor SE, Fingleton B, Kassiri Z, et al. Abnormal TNF activity in Timp3-/- mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet. 2004;36:969–977. [PubMed]
17. Doggrell SA. TACE inhibition: a new approach to treating inflammation. Expert Opin Investig Drugs. 2002;11:1003–1006. [PubMed]
18. Moss ML, Sklair-Tavron L, Nudelman R. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008;4:300–309. [PubMed]
19. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis. 2001;21:373–384. [PubMed]
20. Hemmann S, Graf J, Roderfeld M, Roeb E. Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol. 2007;46:955–975. [PubMed]
21. Uchinami H, Seki E, Brenner DA, D'Armiento J. Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology. 2006;44:420–429. [PubMed]
22. Cauwe B, Van den Steen PE, Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol. 2007;42:113–185. [PubMed]
23. Morrison CJ, Butler GS, Rodriguez D, Overall CM. Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr Opin Cell Biol. 2009;21:645–653. [PubMed]
24. Murphy G, Murthy A, Khokha R. Clipping, shedding and RIPping keep immunity on cue. Trends Immunol. 2008;29:75–82. [PubMed]
25. Taub R. Hepatoprotection via the IL-6/Stat3 pathway. J Clin Invest. 2003;112:978–980. [PMC free article] [PubMed]
26. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest. 2005;115:56–65. [PMC free article] [PubMed]
27. Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007;6:480–498. [PubMed]
28. Wielockx B, Lannoy K, Shapiro SD, Itoh T, Itohara S, et al. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat Med. 2001;7:1202–1208. [PubMed]
29. Hamada T, Fondevila C, Busuttil RW, Coito AJ. Metalloproteinase-9 deficiency protects against hepatic ischemia/reperfusion injury. Hepatology. 2008;47:186–198. [PubMed]
30. Olle EW, Ren X, McClintock SD, Warner RL, Deogracias MP, et al. Matrix metalloproteinase-9 is an important factor in hepatic regeneration after partial hepatectomy in mice. Hepatology. 2006;44:540–549. [PubMed]
31. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, et al. An essential role for ectodomain shedding in mammalian development. Science. 1998;282:1281–1284. [PubMed]
32. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003;253:269–285. [PubMed]
33. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827–839. [PubMed]
34. Clements JM, Cossins JA, Wells GM, Corkill DJ, Helfrich K, et al. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J Neuroimmunol. 1997;74:85–94. [PubMed]
35. Arthur MJ, Friedman SL, Roll FJ, Bissell DM. Lipocytes from normal rat liver release a neutral metalloproteinase that degrades basement membrane (type IV) collagen. J Clin Invest. 1989;84:1076–1085. [PMC free article] [PubMed]
36. Magness ST, Bataller R, Yang L, Brenner DA. A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology. 2004;40:1151–1159. [PubMed]
37. Winwood PJ, Schuppan D, Iredale JP, Kawser CA, Docherty AJ, et al. Kupffer cell-derived 95-kd type IV collagenase/gelatinase B: characterization and expression in cultured cells. Hepatology. 1995;22:304–315. [PubMed]
38. Olaso E, Ikeda K, Eng FJ, Xu L, Wang LH, et al. DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. J Clin Invest. 2001;108:1369–1378.39. [PMC free article] [PubMed]
39. Yoshiji H, Kuriyama S, Miyamoto Y, Thorgeirsson UP, Gomez DE, et al. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology. 2000;32:1248–1254. [PubMed]
40. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology. 2002;36:850–860. [PubMed]
41. Mohammed FF, Pennington CJ, Kassiri Z, Rubin JS, Soloway PD, et al. Metalloproteinase inhibitor TIMP-1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration. Hepatology. 2005;41:857–867. [PubMed]
42. Czaja MJ, Xu J, Alt E. Prevention of carbon tetrachloride-induced rat liver injury by soluble tumor necrosis factor receptor. Gastroenterology. 1995;108:1849–1854. [PubMed]
43. Bahcecioglu IH, Koca SS, Poyrazoglu OK, Yalniz M, Ozercan IH, et al. Hepatoprotective effect of infliximab, an anti-TNF-alpha agent, on carbon tetrachloride-induced hepatic fibrosis. Inflammation. 2008;31:215–221. [PubMed]
44. Simeonova PP, Gallucci RM, Hulderman T, Wilson R, Kommineni C, et al. The role of tumor necrosis factor-alpha in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride. Toxicol Appl Pharmacol. 2001;177:112–120. [PubMed]
45. Sudo K, Yamada Y, Moriwaki H, Saito K, Seishima M. Lack of tumor necrosis factor receptor type 1 inhibits liver fibrosis induced by carbon tetrachloride in mice. Cytokine. 2005;29:236–244. [PubMed]
46. Knittel T, Mehde M, Grundmann A, Saile B, Scharf JG, et al. Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat. Histochem Cell Biol. 2000;113:443–453. [PubMed]
47. Kahraman A, Bronk SF, Cazanave S, Werneburg NW, Mott JL, et al. Matrix metalloproteinase inhibitor, CTS-1027, attenuates liver injury and fibrosis in the bile duct-ligated mouse. Hepatol Res. 2009;39:805–813. [PMC free article] [PubMed]
48. ClinicalTrials.gov. Identifier: NCT01051921. 2010. Available at www.clinicaltrials.gov (Accessed May 21, 2010)
49. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer. 2002;86:1864–1870. [PMC free article] [PubMed]
50. Rosenbaum E, Zahurak M, Sinibaldi V, Carducci MA, Pili R, et al. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial. Clin Cancer Res. 2005;11:4437–4443. [PubMed]
51. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002;295:2387–2392. [PubMed]
52. Schneider BS, Maimon J, Golub LM, Ramamurthy NS, Greenwald RA. Tetracyclines inhibit intracellular muscle proteolysis in vitro. Biochem Biophys Res Commun. 1992;188:767–772. [PubMed]
53. Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med. 2006;354:2621–2622. [PubMed]
54. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther. 1997;75:69–75. [PubMed]
55. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321. [PubMed]
56. Jamall IS, Finelli VN, Que Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem. 1981;112:70–75. [PubMed]
57. Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D. Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol. 2005;43:1045–1054. [PubMed]
58. Popov Y, Patsenker E, Bauer M, Niedobitek E, Schulze-Krebs A, et al. Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem. 2006;281:15090–15098. [PubMed]
59. Popov Y, Patsenker E, Stickel F, Zaks J, Bhaskar KR, et al. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol. 2008;48:453–464. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science